<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78</article-id><article-id pub-id-type="publisher-id">2009MOLVIS0009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Single nucleotide polymorphisms of the tenomodulin gene (<italic>TNMD</italic>) in age-related macular degeneration</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Tolppanen</surname><given-names>Anna-Maija</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nevalainen</surname><given-names>Tanja</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kolehmainen</surname><given-names>Marjukka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Seitsonen</surname><given-names>Sanna</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Immonen</surname><given-names>Ilkka</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Uusitupa</surname><given-names>Matti</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaarniranta</surname><given-names>Kai</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pulkkinen</surname><given-names>Leena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of Clinical Nutrition and Food and Health Research Centre, School of Public Health and Clinical Nutrition, University of Kuopio, Kuopio, Finland</aff><aff id="aff2"><label>2</label>Department of Ophthalmology, Kuopio University Hospital, Kuopio, Finland</aff><aff id="aff3"><label>3</label>Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland</aff></contrib-group><author-notes><fn><p>The first two authors contributed equally to this work.</p></fn><corresp id="cor1">Correspondence to: Anna-Maija Tolppanen, University of Kuopio, Department of Clinical Nutrition and Food and Health Research Centre, School of Public Health and Clinical Nutrition, P.O. Box 1627, Fl-70211 Kuopio, Finland; Phone: +358403552247; FAX: +35817162792; email: <email xlink:href="anna-maija.tolppanen@uku.fi">anna-maija.tolppanen@uku.fi</email></corresp></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2009</year></pub-date><volume>15</volume><fpage>762</fpage><lpage>770</lpage><history><date date-type="received"><day>12</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>10</day><month>4</month><year>2009</year></date></history><permissions><copyright-year>2009</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>Tenomodulin (<italic>TNMD)</italic> is located in the X-chromosome encoding a putative angiogenesis inhibitor which is expressed in retina. Associations of single nucleotide polymorphisms of <italic>TNMD</italic> with the prevalence of age-related macular degeneration (AMD) were examined.</p></sec><sec sec-type="methods"><title>Methods</title><p>Six markers covering 75% of the common sequence variation in the coding region of <italic>TNMD</italic> and 10 kb up- and downstream were genotyped in a sample consisting of 89 men and 175 women with exudative AMD, 18 men and 25 women with atrophic AMD, and 55 men and 113 women without AMD. All participants were over 65 years old and did not have diabetes mellitus. Due to the chromosomal locus, the association of genotypes with AMD was assessed genderwise.</p></sec><sec><title>Results</title><p>Three markers, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>, were associated with a risk of AMD in women. In comparison to women with other genotypes, the women who were homozygous for the minor allele (genotypes <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>-TT or <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>-CC) had 2.6 fold (p=0.021) or 1.9 fold (p=0.067) risk for having AMD, respectively. These differences were due to the unequal prevalence of exudative AMD. In comparison to women who were homozygous for the major alleles, the women with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>-TT genotype had a 2.8 fold risk (p=0.021 in additive model; p=0.022 in recessive model) for exudative AMD, and the women with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>-CC genotype had a 1.8 fold risk (p=0.09 in additive model; p=0.038 in recessive model). Furthermore, women carrying the rare <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>-AA genotype had a significantly smaller risk for having AMD than women with the other genotypes (odds ratio 0.083; p=0.001 in recessive model), but due to the low frequency of this genotype, this finding must be interpreted cautiously. The false discovery rate was &#x0003c;10% for all of the aforementioned results.</p></sec><sec><title>Conclusions</title><p>On the basis of the putative antiangiogenic role of TNMD and the present genetic associations of <italic>TNMD</italic> with AMD in women, we suggest that <italic>TNMD</italic> could be a novel candidate gene for AMD. These results should be confirmed in further studies.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Tolppanen</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the elderly [<xref ref-type="bibr" rid="r1">1</xref>]. It is attributable to degenerative tissue alterations occurring at the interface between the neural retina and underlying choroid [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r3">3</xref>]. AMD can be divided into atrophic and exudative forms. The atrophic form is more common and accounts for approximately 80% of AMD cases. However, the exudative form accounts for the majority of advanced cases [<xref ref-type="bibr" rid="r4">4</xref>]. The disease etiology is multifactorial&#x02014;i.e., in addition to a substantial genetic component [<xref ref-type="bibr" rid="r5">5</xref>], aging, smoking, high body mass index, hypertension, and hypercholesterolemia predispose to AMD [<xref ref-type="bibr" rid="r6">6</xref>&#x02013;<xref ref-type="bibr" rid="r11">11</xref>]. Choroidal neovascularization and leakage from the blood vessels are diagnostic markers for exudative AMD. Oxidative stress, ischemia, or inflammation can induce proliferative processes in the choroidal endothelial cells, which then evokes the growth of new blood vessels into subretinal or retinal space [<xref ref-type="bibr" rid="r2">2</xref>,<xref ref-type="bibr" rid="r12">12</xref>]. A thickening, calcification, and fragmentation of Bruch&#x02019;s membrane may predispose to the development of choroidal neovascular membranes. The harmful new blood vessels that are diagnostic for exudative AMD grow through Bruch&#x02019;s membrane, where they can disrupt the membrane and leak blood or fluid into the subretinal pigment epithelial space [<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r4">4</xref>]. This can evoke damage to the photoreceptor layer and result in vision abnormalities or even total loss of vision [<xref ref-type="bibr" rid="r3">3</xref>,<xref ref-type="bibr" rid="r4">4</xref>].</p><p>The importance of genetic risk factors, specifically of those related to the complement system, has been highlighted in several studies. An association has been observed between the Y402H polymorphism (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1061170">rs1061170</ext-link>) of the complement factor H gene and AMD in several populations [<xref ref-type="bibr" rid="r13">13</xref>&#x02013;<xref ref-type="bibr" rid="r19">19</xref>]. Furthermore, an association between the LOC387715/HTRA1 locus and AMD in populations of different origin has been documented [<xref ref-type="bibr" rid="r20">20</xref>&#x02013;<xref ref-type="bibr" rid="r28">28</xref>]. One common polymorphism (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2230199">rs2230199</ext-link>) in the complement component 3 has also been associated with AMD [<xref ref-type="bibr" rid="r29">29</xref>,<xref ref-type="bibr" rid="r30">30</xref>]. Other putative candidates include genes related to fatty acid metabolism, such as apolipoprotein E [<xref ref-type="bibr" rid="r31">31</xref>,<xref ref-type="bibr" rid="r32">32</xref>], ATP-binding cassette, subfamily A, member 4 [<xref ref-type="bibr" rid="r33">33</xref>,<xref ref-type="bibr" rid="r34">34</xref>], and elongation of very long chain fatty acids-like 4 [<xref ref-type="bibr" rid="r18">18</xref>], but their roles in the pathogenesis of AMD are controversial.</p><p>Since dysregulated neovascularization is involved in the pathogenesis of AMD, the angiogenesis regulators represent interesting candidate genes. Tenomodulin (TNMD) is a type II transmembrane glycoprotein containing a C-terminal domain with homology to chondromodulin-I, which is a cartilage-derived angiogenesis inhibitor [<xref ref-type="bibr" rid="r35">35</xref>&#x02013;<xref ref-type="bibr" rid="r37">37</xref>]. During the late developmental phase of mouse embryo, <italic>TNMD</italic> mRNA is expressed in the tendon of extraocular muscles, cornea, sensory retina, sclera, lens epithelial cells at the equator, and in the differentiating secondary lens fiber cells [<xref ref-type="bibr" rid="r38">38</xref>]. TNMD has been reported to inhibit angiogenesis by hindering endothelial proliferation and tube formation [<xref ref-type="bibr" rid="r38">38</xref>,<xref ref-type="bibr" rid="r39">39</xref>], but this has not been confirmed in vivo since the <italic>TNMD</italic>-deficient mice did not exhibit any vascular abnormalities when examined by oxygen-induced retinopathy [<xref ref-type="bibr" rid="r40">40</xref>]. Recent results suggest that single nucleotide polymorphisms (SNPs) of <italic>TNMD</italic> are associated with obesity, disturbed glucose metabolism, and conversion from impaired glucose tolerance to type 2 diabetes [<xref ref-type="bibr" rid="r41">41</xref>] as well as with elevated serum levels of systemic immune mediators [<xref ref-type="bibr" rid="r42">42</xref>] and serum lipoproteins [<xref ref-type="bibr" rid="r43">43</xref>]. Due to these connections with vascularization, inflammation, lipid metabolism, and obesity, <italic>TNMD</italic> is an interesting potential new candidate gene for AMD. In addition, the diaphanous <italic>2</italic> Drosophila homolog gene (<italic>DIAPH</italic>), located in the same cytogenetic band Xq-22, has been linked to AMD in a study by Zheng et al. [<xref ref-type="bibr" rid="r44">44</xref>]. In the present study, we investigated the associations of <italic>TNMD</italic> SNPs with AMD.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>The study population consisted of 475 Finnish subjects (162 men, 313 women). A total of 89 men and 175 women had exudative AMD, and 18 men and 25 women had atrophic AMD. Patients with choroidal neovascularization attributable to AMD were given their diagnosis based on fundus photographs and fluorescein angiography in the Department of Ophthalmology of Kuopio University Hospital or Helsinki University Hospital. The control group (no signs of AMD in fundus photographs) consisted of 55 men and 113 women. All participants were over 65 years old and did not have diabetes mellitus. The study was approved by the Ethics Committee of the Helsinki University Eye and Ear Hospital and the tenets of the Declaration of Helsinki were followed. All participants signed an informed consent form. Eligibility criteria was based on biomicroscopy examination, fundus photographs and fluorescein angiography which were performed before the study. The blood samples were stored in &#x02212;80&#x000a0;&#x000b0;C until DNA isolation. DNA was extracted from peripheral blood leucocytes by salt precipitation.</p></sec><sec><title>Genotype analysis</title><p>Six markers covering 75% of the common sequence variation with r<sup>2</sup>&#x0003e;0.8 in the coding region of <italic>TNMD</italic> (15 kb) and 10 kb upstream and downstream from the coding region (35 kb) were selected with the <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/tagger/">Tagger</ext-link> algorithm [<xref ref-type="bibr" rid="r45">45</xref>]. The markers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>, associated with an increased risk of type 2 diabetes [<xref ref-type="bibr" rid="r41">41</xref>] and elevated concentrations of serum acute phase reactants [<xref ref-type="bibr" rid="r42">42</xref>] in our previous studies, were included in the selection procedure.</p><p>Genotyping was performed with TaqMan Allelic Discrimination Assay according to the manufacturer&#x02019;s instructions using ABI Prism 7000 sequence detector (Applied Biosystems, Foster City, CA). The genotyping success rate was 98.5% for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>, 99.6% for <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1204384">rs1204384</ext-link>, and 100% for the markers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>. The error rate for genotyping was calculated by repeating a subset of randomly selected samples representing 6.3% of the study cohort. The error rate was 0% for all markers.</p></sec><sec><title>Statistics</title><p>Haploview software [<xref ref-type="bibr" rid="r46">46</xref>] was used for linkage disequilibrium (LD) and Hardy&#x02013;Weinberg equilibrium analysis, and association studies were performed with SPSS 14.0 for Windows (SPSS, Chicago, IL). The association of the <italic>TNMD</italic> SNPs with the prevalence of AMD was tested with logistic regression analysis. Due to the X-chromosomal location, a genderwise analysis was performed. In women, the association with the prevalence of AMD was assessed with additive, dominant (major allele homozygotes versus other genotypes), and recessive (minor allele homozygotes versus other genotypes) models. The genderwise differences in minor allele frequencies (MAF) were assessed with the &#x003c7;<sup>2</sup>-test. Haplotype analyses were performed with Thesias 3.1 software [<xref ref-type="bibr" rid="r47">47</xref>]. Correction for multiple hypothesis testing was performed with false discovery rate using Q-value 1.0 software. &#x003c0;<sub>0</sub> was estimated with the bootstrap method using &#x003bb; range from 0 to 0.9 by 0.05 [<xref ref-type="bibr" rid="r48">48</xref>]. The false discovery rate for each p-value &#x0003c;0.1 was reported as <italic>q</italic>.</p></sec></sec><sec sec-type="results"><title>Results</title><p>All markers, except <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link> (p=0.002) were in Hardy&#x02013;Weinberg equilibrium. This exception was unlikely due to a genotyping error, as confirmed by genotyping a random subsample of the study population. The pairwise LD pattern and positions of the markers are presented in <xref ref-type="fig" rid="f1">Figure 1</xref>. The genderwise minor allele frequencies are shown in <xref ref-type="table" rid="t1">Table 1</xref>.</p><fig id="f1" fig-type="figure" position="float"><label>Figure 1</label><caption><p>Location of the selected markers along the <italic>TNMD</italic> gene and their pairwise linkage disequilibrium pattern, indicated by D'- (upper) and r2-values (lower). Two haploblocks, defined by solid spine of linkage disequilibrium are denoted by gray shading. The first haploblock consists of markers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link>, and the second consists of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>.</p></caption><graphic xlink:href="mv-v15-762-f1"/></fig><table-wrap id="t1" position="float"><label>Table 1</label><caption><title>The genderwise minor allele frequencies of the genotyped markers.</title></caption><table frame="hsides" rules="groups"><col width="110" span="1"/><col width="152" span="1"/><col width="162" span="1"/><col width="51" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Marker (minor allele)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Minor allele frequencies</bold>&#x02028;<bold>(Men)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Minor allele frequencies (Women)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>p</italic></bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>&#x02028; (A)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.175<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.055<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.00007<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link>&#x02028; (A)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.395<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.386<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.869<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link>&#x02028; (T)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.383<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.197<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.0001<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>&#x02028; (C)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.315<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.279<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.462<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>&#x02028; (T)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.346<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.241<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.036<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1204384">rs1204384</ext-link>&#x02028; (T)</td><td valign="top" align="center" rowspan="1" colspan="1">0.304</td><td valign="top" align="center" rowspan="1" colspan="1">0.198</td><td valign="top" align="center" rowspan="1" colspan="1">0.024</td></tr></tbody></table><table-wrap-foot><p>The minor allele frequencies (MAF) of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> did not differ between the genders. A minor difference was observed in the MAF of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1204384">rs1204384</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link> while the MAF of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link> differed more significantly between men and women. Markers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link> were associated with AMD in women.</p></table-wrap-foot></table-wrap><p>In women, the markers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link> were associated with total prevalence (atrophic or exudative form) of AMD, and a trend was observed with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>. The odds ratios (OR) of the heterozygous women were similar to those observed among women who were major allele homozygotes (data not shown). In contrast, the women homozygous for the minor alleles had significantly different ORs for having AMD than women with other genotypes. In comparison to women with other genotypes, the women who were homozygous for either of the minor alleles <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>-TT or <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>-CC, had 2.6 fold or 1.9 fold risk for having AMD, respectively (<ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>). In addition, women with the rare <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>-AA genotype displayed a significantly smaller risk for having AMD than the women with the other genotypes (odds ratio=0.083, <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>).</p><p>In more specific terms, these differences were due to the unequal prevalence of exudative AMD in the genotype groups. The women with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>-CC genotype had a 2.1 fold risk (p=0.038) for exudative AMD, and the women with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>-TT genotype had a 2.6 fold risk (p=0.022) in comparison to the women with other genotypes of the same markers (p values refer to the recessive model; <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>). The women with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>-AA genotype had a significantly smaller risk for AMD than women with <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>-TT or <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>-TA genotypes (p=0.002; recessive model, <ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>). The OR of heterozygous women did not differ between those observed among the women who were homozygous for the major allele (<ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>). None of the markers were associated with prevalence of AMD among men (<xref ref-type="table" rid="t2">Table 2</xref>). The false discovery rate was less than 10% for all of the abovementioned associations and less than 5%, apart from that of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> with total prevalence of AMD (<italic>q</italic>=0.067).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>The associations of the selected markers of the <italic>TNMD</italic> gene with exudative AMD in men.</title></caption><table frame="hsides" rules="groups"><col width="88" span="1"/><col width="88" span="1"/><col width="88" span="1"/><col width="123" span="1"/><col width="88" span="1"/><col width="7" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Marker</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Number of cases/controls</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR (95%CI)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p</bold></th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78/41<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.112<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11/12<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.482 (0.196&#x02013;1.187)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58/31<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.292<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31/24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.690 (0.347&#x02013;1.374)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57/31<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.359<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32/24<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.725 (0.362&#x02013;1.441)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60/41<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.365<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29/14<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.415 (0.668&#x02013;3.001)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1"><hr/></td></tr><tr><td rowspan="3" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">60/36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.808<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29/19<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.916 (0.450&#x02013;1.864)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td colspan="5" valign="top" align="left" scope="col" rowspan="1"><hr/></td></tr><tr><td rowspan="2" valign="top" align="left" scope="row" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1204384">rs1204384</ext-link></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">61/39<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.84<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT</td><td valign="top" align="center" rowspan="1" colspan="1">27/16</td><td valign="top" align="center" rowspan="1" colspan="1">1.079 (0.516&#x02013;2.256)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Abbreviations: odds ratio (OR); confidence interval (CI). None of the markers was associated with the prevalence of AMD in men.</p></table-wrap-foot></table-wrap><p>Haplotype analyses were performed according to the two LD-based haploblocks, one consisting of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link> and the other involving <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>. Additional analyses were performed for combinations of individual markers that were associated with AMD (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>). The results of haplotype analyses were in line with the results of single marker analyses in women, but neither of these approaches revealed a haplotype that would explain the results substantially better than the individual markers (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>Associations of the <italic>TNMD</italic> haplotypes with total AMD (exudative and atrophic) and exudative AMD in women.</title></caption><table frame="hsides" rules="groups"><col width="67" span="1"/><col width="61" span="1"/><col width="62" span="1"/><col width="66" span="1"/><col width="114" span="1"/><col width="48" span="1"/><col width="114" span="1"/><col width="42" span="1"/><thead><tr><th rowspan="2" colspan="3" valign="top" align="center" scope="colgroup"><bold>Markers</bold><hr/></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1"><bold>Frequency</bold><hr/></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Total AMD</bold></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><bold>Exudative AMD</bold></th></tr></thead><tbody><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1"><bold>OR (95% CI)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>OR (95% CI)</bold><hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>p</bold><hr/></td></tr><tr><td colspan="8" valign="top" align="center" scope="col" rowspan="1">Haploblock 1<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=11798018">rs11798018</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.437<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.329<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.821 (0.541- 1.244)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.35<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.918 (0.618&#x02013;1.365)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.674<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.23<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.921 (0.627&#x02013;1.353)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.681<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.853 (0.557&#x02013;1.306)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.465<hr/></td></tr><tr><td colspan="8" valign="top" align="center" scope="col" rowspan="1">Haploblock 2<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.637<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.287<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.411 (0.972&#x02013;2.047)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.319<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.431 (0.979&#x02013;2.091)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.064<hr/></td></tr><tr><td colspan="8" valign="top" align="center" scope="col" rowspan="1">Markers associated with AMD in women<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.513<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">T<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.288<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.318 (0.875&#x02013;1.986)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.187<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.330 (0.877&#x02013;2.017)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.18<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">A</td><td valign="top" align="center" rowspan="1" colspan="1">T</td><td valign="top" align="center" rowspan="1" colspan="1">C</td><td valign="top" align="center" rowspan="1" colspan="1">0.084</td><td valign="top" align="center" rowspan="1" colspan="1">0.487 (0.241&#x02013;0.986)</td><td valign="top" align="center" rowspan="1" colspan="1">0.046</td><td valign="top" align="center" rowspan="1" colspan="1">0.475 (0.226&#x02013;0.999)</td><td valign="top" align="center" rowspan="1" colspan="1">0.05</td></tr></tbody></table><table-wrap-foot><p>Haploblocks 1 and 2 are defined on the basis of solid spine of LD. In addition, a 3-marker haplotype was constructed of those markers that were associated with AMD in women. The haplotype analyses did not reveal a haplotype that would explain the results substantially better than the single-marker analyses. Abbreviations: odds ratio (OR); confidence interval (CI).</p></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>Discussion</title><p>According to the results of the present study, genetic variation in the <italic>TNMD</italic> gene is associated with the prevalence of AMD in women. The genotypes <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>-CC and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link>-TT that associated with a higher prevalence of exudative AMD among women in the present study (<ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>), were linked with higher serum concentrations of macrophage migration inhibitory factor and chemokine, CC motif ligand 5 in women [<xref ref-type="bibr" rid="r42">42</xref>]. The same markers were associated with higher serum acute phase reactant concentrations among men [<xref ref-type="bibr" rid="r42">42</xref>]. In addition, the <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>-AA genotype was associated with a lower prevalence of exudative AMD among women (<ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>), but due to the low frequency of this genotype (16 out of 313 women), this finding must be interpreted cautiously. We did not observe associations with atrophic AMD, which was likely due to the small number of cases as the main aim of the study was to detect genetic risk factors for exudative AMD. In addition to single-marker analyses, haplotype analyses was performed, but they did not provide additional information (<ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link> and <xref ref-type="table" rid="t3">Table 3</xref>). This may be because the distribution of haplotypes that contained the individual risk alleles was almost identical to the individual allele frequencies. Since there were some missing genotypes, the number of people in the haplotype analysis was slightly lower than in the single marker analyses. This may also account for the weaker associations observed in the haplotype analyses.</p><p>The gender difference may arise from the genetic locus (Xq-22). The expression and function of X-chromosomal genes differ between genders, partially because of the variation in gene dosages and the random inactivation of one of the X-chromosomes in women [<xref ref-type="bibr" rid="r49">49</xref>]. Since the expression levels of <italic>TNMD</italic> mRNA in the adipose tissue of women are double that encountered in men [<xref ref-type="bibr" rid="r50">50</xref>], it seems that the <italic>TNMD</italic> locus is able to escape the X-inactivation. The <italic>TNMD</italic> locus is also relatively distant from the X-inactivation center. Genomic imprinting can also result in different gene expression levels, since women are normally mosaic for maternal and paternal active X-chromosomes; men harbor only the maternal X-chromosome and therefore express the maternally inherited genes in that locus [<xref ref-type="bibr" rid="r51">51</xref>]. In addition, the cellular microenvironment can differ between men and women, due to differences in hormone levels and gene expression [<xref ref-type="bibr" rid="r52">52</xref>]. However, we cannot rule out the possibility that the study was underpowered to detect these associations in men. The observed differences in proportions were smaller than 0.1, and the number of men included in this study population was probably not high enough to detect differences of this magnitude. The MAF distribution of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> was similar in both genders and therefore the association of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link> with AMD does not result from the imbalance in the allele distribution between men and women. Gender differences were observed in the MAF of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>. It is difficult to speculate whether the associations of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1155974">rs1155974</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>, which were observed in women, result from gender differences in MAFs; differences of equal magnitude were observed with two other markers (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=5966709">rs5966709</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=1204384">rs1204384</ext-link>) that were not associated with the prevalence of AMD.</p><p>In vivo experiments in mice with oxygen-induced retinopathy have revealed that a lack of <italic>TNMD</italic> does not result in abnormal angiogenesis or retinal neovascularization [<xref ref-type="bibr" rid="r40">40</xref>]. Since the regulation of angiogenesis is a multifactorial process, it is possible that other factors might have compensated for the absence of <italic>TNMD.</italic> The age-associated factors can also vary between species. In addition, mice lack the normal macula and cones and therefore the regulation of retinal neovascularization in that species might be different from that in the human eye. In exudative AMD, neovascularization is evoked by a proliferation of abnormal choroidal blood vessels behind the retina. The multifactorial etiology of vascular dysregulation in AMD is not fully understood, but the expression levels of many stimulatory and inhibitory regulators of neovascularization are known to be altered during pathogenesis [<xref ref-type="bibr" rid="r12">12</xref>,<xref ref-type="bibr" rid="r53">53</xref>,<xref ref-type="bibr" rid="r54">54</xref>]. For example, vascular endothelial growth factor (VEGF), is known to be involved in choroidal neovascularization [<xref ref-type="bibr" rid="r54">54</xref>] and accordingly, VEGF-blocking compounds are emerging as highly successful treatments for exudative AMD [<xref ref-type="bibr" rid="r55">55</xref>&#x02013;<xref ref-type="bibr" rid="r58">58</xref>]. This provides further evidence for the importance of angiogenesis regulators in AMD and supports the theory of a disrupted balance between stimulators and inhibitors of neovascularization in the pathogenesis of exudative AMD.</p><p>The genetic association studies on the role of VEGF polymorphisms in exudative AMD have delivered conflicting results [<xref ref-type="bibr" rid="r59">59</xref>&#x02013;<xref ref-type="bibr" rid="r62">62</xref>], but interestingly, polymorphisms of the gene encoding antiangiogenic pigment epithelial growth factor have been linked to AMD [<xref ref-type="bibr" rid="r63">63</xref>,<xref ref-type="bibr" rid="r64">64</xref>]. In relation to these previous association studies with angiogenesis regulators, the associations between <italic>TNMD</italic> sequence variation and exudative AMD point to an interesting hypothesis on the regulatory role of TNMD in choroidal neovascularization and exudative AMD. It is important to note that the false discovery rate for the associations observed in women was low, suggesting that <italic>TNMD</italic> is a promising new candidate gene for AMD. The same cytogenetic band has been linked to AMD by Zheng et al., who also reported gender-specific associations with the <italic>DIAPH2</italic> [<xref ref-type="bibr" rid="r44">44</xref>]. Therefore, despite the lack of a replication sample, our results are supported by the findings of this previous study. We recognize the need for the replication of these findings in other study populations. Functional studies are needed to reveal the potential mechanisms accounting for these associations.</p></sec></body><back><app-group><app><title>Appendix 1. The association of <italic>TNMD</italic> SNPs with AMD in women.</title><p>The associations of the selected markers of the <italic>TNMD</italic> gene with the prevalence of total (athropic or exudative) and exudative AMD are reported according to additive and recessive (minor allele homozygotes versus other genotypes) models. False discovery rate (q) is indicated only for p&#x0003c;0.1. The markers <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=7890586">rs7890586</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2073163">rs2073163</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=155974">rs155974</ext-link> were associated with total and exudative AMDTo access the data, click or select the words &#x0201c;<ext-link ext-link-type="uri" xlink:href="http://www.molvis.org/molvis/v15/a78/app-1.pdf">Appendix 1</ext-link>.&#x0201d; This will initiate the download of a pdf that contains the file. False discovery rate <italic>q</italic> is reported only for p&#x0003c;0.1. Abbreviations: odds ratio (OR); confidence interval (CI).</p></app></app-group><ack><title>Acknowledgments</title><p>We gratefully acknowledge Ms. P&#x000e4;ivi Turunen for excellent technical assistance. This study was funded by the Finnish Graduate School on Applied Bioscience: Bioengineering, Food and Nutrition, Environment (A.M.T.), Sigrid Juselius Foundation, Academy of Finland (grants 117844, 211497, M.U.; 209445, M.K.), the EVO fund of the Kuopio University Hospital (5179 and 5198, M.U.; 5503709, T.N.), from the Ministry of Health and Social Affairs, Emil Aaltonen Foundation (K.K.), the Finnish Cultural Foundation and its North Savo Fund (K.K.), the Finnish Eye Foundation (K.K., T.N.), the Finnish Eye and Tissue Bank Foundation (K.K.), and the Finnish Funding Agency for Technology and Innovation (K.K.).</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="book">Bressler SB, Brown GC, Flynn HWJ. Acquired diseases affecting macula. In: Deutsch TA, Grand MG, Liesegang TJ, editors. Basic and clinical science course. San Fransisco: The Foundation of the American Academy of Ophthalmology; 2001</citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>S</given-names></name><name><surname>Koh</surname><given-names>H</given-names></name><name><surname>Phil</surname><given-names>M</given-names></name><name><surname>Henson</surname><given-names>D</given-names></name><name><surname>Boulton</surname><given-names>M</given-names></name></person-group><article-title>The role of oxidative stress in the pathogenesis of age-related macular degeneration.</article-title><source>Surv Ophthalmol</source><year>2000</year><volume>45</volume><fpage>115</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11033038</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="book">Holz FG, Pauleikhoff D, Spade RF, Bird AC. Genetics of AMD. In: Holz FG, Pauleikhoff D, Spade RF, Bird AC, editors. Age-related macular degeneration Berlin Heidelberg: Springer-Verlag; 2004. p. 24&#x02013;30.</citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gehrs</surname><given-names>KM</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Hageman</surname><given-names>GS</given-names></name></person-group><article-title>Age-related macular degeneration&#x02013;emerging pathogenetic and therapeutic concepts.</article-title><source>Ann Med</source><year>2006</year><volume>38</volume><fpage>450</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17101537</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>JM</given-names></name><name><surname>Cote</surname><given-names>J</given-names></name><name><surname>Page</surname><given-names>WF</given-names></name><name><surname>Aggen</surname><given-names>SH</given-names></name><name><surname>Neale</surname><given-names>MC</given-names></name></person-group><article-title>The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences.</article-title><source>Arch Ophthalmol</source><year>2005</year><volume>123</volume><fpage>321</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15767473</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>W</given-names></name><name><surname>Mitchell</surname><given-names>P</given-names></name></person-group><article-title>Family history and age-related maculopathy: the Blue Mountains Eye Study.</article-title><source>Aust N Z J Ophthalmol</source><year>1998</year><volume>26</volume><fpage>203</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9717749</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyman</surname><given-names>L</given-names></name><name><surname>Neborsky</surname><given-names>R</given-names></name></person-group><article-title>Risk factors for age-related macular degeneration: an update.</article-title><source>Curr Opin Ophthalmol</source><year>2002</year><volume>13</volume><fpage>171</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12011686</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buch</surname><given-names>H</given-names></name><name><surname>Vinding</surname><given-names>T</given-names></name><name><surname>la Cour</surname><given-names>M</given-names></name><name><surname>Jensen</surname><given-names>GB</given-names></name><name><surname>Prause</surname><given-names>JU</given-names></name><name><surname>Nielsen</surname><given-names>NV</given-names></name></person-group><article-title>Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study.</article-title><source>Acta Ophthalmol Scand</source><year>2005</year><volume>83</volume><fpage>409</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">16029262</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>R</given-names></name><name><surname>Ikram</surname><given-names>MK</given-names></name><name><surname>Vingerling</surname><given-names>JR</given-names></name><name><surname>Witteman</surname><given-names>JC</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name></person-group><article-title>Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>3771</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12939290</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>R</given-names></name><name><surname>Klaver</surname><given-names>CC</given-names></name><name><surname>Vingerling</surname><given-names>JR</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name></person-group><article-title>Epidemiology of agerelated maculopathy: a review.</article-title><source>Eur J Epidemiol</source><year>2003</year><volume>18</volume><fpage>845</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">14561043</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Klein</surname><given-names>BE</given-names></name><name><surname>Tomany</surname><given-names>SC</given-names></name><name><surname>Cruickshanks</surname><given-names>KJ</given-names></name></person-group><article-title>The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study.</article-title><source>Ophthalmology</source><year>2003</year><volume>110</volume><fpage>1273</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">12799274</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donoso</surname><given-names>LA</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><name><surname>Callahan</surname><given-names>A</given-names></name><name><surname>Hageman</surname><given-names>G</given-names></name></person-group><article-title>The role of inflammation in the pathogenesis of age-related macular degeneration.</article-title><source>Surv Ophthalmol</source><year>2006</year><volume>51</volume><fpage>137</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16500214</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>AO</given-names></name><name><surname>Ritter</surname><given-names>R</given-names><suffix>3rd</suffix></name><name><surname>Abel</surname><given-names>KJ</given-names></name><name><surname>Manning</surname><given-names>A</given-names></name><name><surname>Panhuysen</surname><given-names>C</given-names></name><name><surname>Farrer</surname><given-names>LA</given-names></name></person-group><article-title>Complement factor H polymorphism and age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>421</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15761121</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hageman</surname><given-names>GS</given-names></name><name><surname>Anderson</surname><given-names>DH</given-names></name><name><surname>Johnson</surname><given-names>LV</given-names></name><name><surname>Hancox</surname><given-names>LS</given-names></name><name><surname>Taiber</surname><given-names>AJ</given-names></name><name><surname>Hardisty</surname><given-names>LI</given-names></name><name><surname>Hageman</surname><given-names>JL</given-names></name><name><surname>Stockman</surname><given-names>HA</given-names></name><name><surname>Borchardt</surname><given-names>JD</given-names></name><name><surname>Gehrs</surname><given-names>KM</given-names></name><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Russell</surname><given-names>SR</given-names></name><name><surname>Klaver</surname><given-names>CC</given-names></name><name><surname>Barbazetto</surname><given-names>I</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name><name><surname>Yannuzzi</surname><given-names>LA</given-names></name><name><surname>Barile</surname><given-names>GR</given-names></name><name><surname>Merriam</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>RT</given-names></name><name><surname>Olsh</surname><given-names>AK</given-names></name><name><surname>Bergeron</surname><given-names>J</given-names></name><name><surname>Zernant</surname><given-names>J</given-names></name><name><surname>Merriam</surname><given-names>JE</given-names></name><name><surname>Gold</surname><given-names>B</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name></person-group><article-title>A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>7227</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15870199</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Hauser</surname><given-names>MA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Olson</surname><given-names>LM</given-names></name><name><surname>Gallins</surname><given-names>P</given-names></name><name><surname>Spencer</surname><given-names>KL</given-names></name><name><surname>Kwan</surname><given-names>SY</given-names></name><name><surname>Noureddine</surname><given-names>M</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Complement factor H variant increases the risk of age-related macular degeneration.</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>419</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15761120</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souied</surname><given-names>EH</given-names></name><name><surname>Leveziel</surname><given-names>N</given-names></name><name><surname>Richard</surname><given-names>F</given-names></name><name><surname>Dragon-Durey</surname><given-names>MA</given-names></name><name><surname>Coscas</surname><given-names>G</given-names></name><name><surname>Soubrane</surname><given-names>G</given-names></name><name><surname>Benlian</surname><given-names>P</given-names></name><name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name></person-group><article-title>Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population.</article-title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>1135</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">16379025</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>LI</given-names></name><name><surname>Chen</surname><given-names>SJ</given-names></name><name><surname>Cheng</surname><given-names>CY</given-names></name><name><surname>Yen</surname><given-names>MY</given-names></name><name><surname>Lee</surname><given-names>FL</given-names></name><name><surname>Lin</surname><given-names>MW</given-names></name><name><surname>Hsu</surname><given-names>WM</given-names></name><name><surname>Wei</surname><given-names>YH</given-names></name></person-group><article-title>Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>3242</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16877387</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seitsonen</surname><given-names>S</given-names></name><name><surname>Lemmel&#x000e4;</surname><given-names>S</given-names></name><name><surname>Holopainen</surname><given-names>J</given-names></name><name><surname>Tommila</surname><given-names>P</given-names></name><name><surname>Ranta</surname><given-names>P</given-names></name><name><surname>Kotamies</surname><given-names>A</given-names></name><name><surname>Moilanen</surname><given-names>J</given-names></name><name><surname>Palosaari</surname><given-names>T</given-names></name><name><surname>Kaarniranta</surname><given-names>K</given-names></name><name><surname>Meri</surname><given-names>S</given-names></name><name><surname>Immonen</surname><given-names>I</given-names></name><name><surname>J&#x000e4;rvel&#x000e4;</surname><given-names>I</given-names></name></person-group><article-title>Analysis of variants in the complement factor H, the elongation of very long chain fatty acids-like 4 and the hemicentin 1 genes of age-related macular degeneration in the Finnish population.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>796</fpage><lpage>801</lpage><pub-id pub-id-type="pmid">16885922</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seitsonen</surname><given-names>SP</given-names></name><name><surname>Onkamo</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Xiong</surname><given-names>M</given-names></name><name><surname>Tommila</surname><given-names>PV</given-names></name><name><surname>Ranta</surname><given-names>PH</given-names></name><name><surname>Holopainen</surname><given-names>JM</given-names></name><name><surname>Moilanen</surname><given-names>JA</given-names></name><name><surname>Palosaari</surname><given-names>T</given-names></name><name><surname>Kaarniranta</surname><given-names>K</given-names></name><name><surname>Meri</surname><given-names>S</given-names></name><name><surname>Immonen</surname><given-names>IR</given-names></name><name><surname>J&#x000e4;rvel&#x000e4;</surname><given-names>IE</given-names></name></person-group><article-title>Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration.</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e3833</fpage><pub-id pub-id-type="pmid">19048105</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Fritsche</surname><given-names>LG</given-names></name><name><surname>Keilhauer</surname><given-names>CN</given-names></name><name><surname>Lichtner</surname><given-names>P</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>BH</given-names></name></person-group><article-title>Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.</article-title><source>Hum Mol Genet</source><year>2005</year><volume>14</volume><fpage>3227</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16174643</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>RJ</given-names></name><name><surname>Bojanowski</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Rochtchina</surname><given-names>E</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names><suffix>3rd</suffix></name><name><surname>Mitchell</surname><given-names>P</given-names></name><name><surname>Chan</surname><given-names>CC</given-names></name><name><surname>Tuo</surname><given-names>J</given-names></name></person-group><article-title>The LOC387715 polymorphism and age-related macular degeneration: replication in three case-control samples.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2007</year><volume>48</volume><fpage>1128</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17325155</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanimoto</surname><given-names>S</given-names></name><name><surname>Tamura</surname><given-names>H</given-names></name><name><surname>Ue</surname><given-names>T</given-names></name><name><surname>Yamane</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Kawakami</surname><given-names>H</given-names></name><name><surname>Kiuchi</surname><given-names>Y</given-names></name></person-group><article-title>A polymorphism of LOC387715 gene is associated with age-related macular degeneration in the Japanese population.</article-title><source>Neurosci Lett</source><year>2007</year><volume>414</volume><fpage>71</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17194541</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Camp</surname><given-names>NJ</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>Z</given-names></name><name><surname>Gibbs</surname><given-names>D</given-names></name><name><surname>Cameron</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Pearson</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chien</surname><given-names>J</given-names></name><name><surname>Dewan</surname><given-names>A</given-names></name><name><surname>Harmon</surname><given-names>J</given-names></name><name><surname>Bernstein</surname><given-names>PS</given-names></name><name><surname>Shridhar</surname><given-names>V</given-names></name><name><surname>Zabriskie</surname><given-names>NA</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name><name><surname>Howes</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name></person-group><article-title>A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>992</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17053109</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Lei</surname><given-names>C</given-names></name><name><surname>Cameron</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name></person-group><article-title>HTRA1 variant increases risk to neovascular age-related macular degeneration in Chinese population.</article-title><source>Vision Res</source><year>2007</year><volume>47</volume><fpage>3120</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17904186</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dewan</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Hartman</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>SS</given-names></name><name><surname>Liu</surname><given-names>DT</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Tam</surname><given-names>PO</given-names></name><name><surname>Chan</surname><given-names>WM</given-names></name><name><surname>Lam</surname><given-names>DS</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name><name><surname>Barnstable</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>CP</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name></person-group><article-title>HTRA1 promoter polymorphism in wet age-related macular degeneration.</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>989</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">17053108</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Horie-Inoue</surname><given-names>K</given-names></name><name><surname>Kohda</surname><given-names>M</given-names></name><name><surname>Kawasaki</surname><given-names>I</given-names></name><name><surname>Gehlbach</surname><given-names>PL</given-names></name><name><surname>Awata</surname><given-names>T</given-names></name><name><surname>Yoneya</surname><given-names>S</given-names></name><name><surname>Okazaki</surname><given-names>Y</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name></person-group><article-title>Association of the HTRA1 gene variant with age-related macular degeneration in the Japanese population.</article-title><source>J Hum Genet</source><year>2007</year><volume>52</volume><fpage>636</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">17568988</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>DeWan</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sakamoto</surname><given-names>R</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Minami</surname><given-names>M</given-names></name><name><surname>Obazawa</surname><given-names>M</given-names></name><name><surname>Mizota</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Takagi</surname><given-names>I</given-names></name><name><surname>Hoh</surname><given-names>J</given-names></name><name><surname>Iwata</surname><given-names>T</given-names></name></person-group><article-title>HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>545</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17438519</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weger</surname><given-names>M</given-names></name><name><surname>Renner</surname><given-names>W</given-names></name><name><surname>Steinbrugger</surname><given-names>I</given-names></name><name><surname>K&#x000f6;fer</surname><given-names>K</given-names></name><name><surname>Wedrich</surname><given-names>A</given-names></name><name><surname>Groselj-Strele</surname><given-names>A</given-names></name><name><surname>El-Shabrawi</surname><given-names>Y</given-names></name><name><surname>Schmut</surname><given-names>O</given-names></name><name><surname>Haas</surname><given-names>A</given-names></name></person-group><article-title>Association of the HTRA1 &#x02212;625G&#x0003e;A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>1274</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17679948</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Sepp</surname><given-names>T</given-names></name><name><surname>Matharu</surname><given-names>BK</given-names></name><name><surname>Khan</surname><given-names>JC</given-names></name><name><surname>Thurlby</surname><given-names>DA</given-names></name><name><surname>Shahid</surname><given-names>H</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Morgan</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>AF</given-names></name><name><surname>Armbrecht</surname><given-names>AM</given-names></name><name><surname>Dhillon</surname><given-names>B</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Redmond</surname><given-names>E</given-names></name><name><surname>Bird</surname><given-names>AC</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name><collab>Genetic Factors in AMD Study Group.</collab></person-group><article-title>Complement C3 variant and the risk of age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>553</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">17634448</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maller</surname><given-names>JB</given-names></name><name><surname>Fagerness</surname><given-names>JA</given-names></name><name><surname>Reynolds</surname><given-names>RC</given-names></name><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Seddon</surname><given-names>JM</given-names></name></person-group><article-title>Variation in complement factor 3 is associated with risk of age-related macular degeneration.</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>1200</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">17767156</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Klaver</surname><given-names>C</given-names></name><name><surname>Saunders</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>E</given-names></name><name><surname>De La Paz</surname><given-names>M</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Small</surname><given-names>K</given-names></name><name><surname>Udar</surname><given-names>N</given-names></name><name><surname>Ong</surname><given-names>J</given-names></name><name><surname>Chalukya</surname><given-names>M</given-names></name><name><surname>Nesburn</surname><given-names>A</given-names></name><name><surname>Kenney</surname><given-names>C</given-names></name><name><surname>Domurath</surname><given-names>R</given-names></name><name><surname>Hogan</surname><given-names>M</given-names></name><name><surname>Mah</surname><given-names>T</given-names></name><name><surname>Conley</surname><given-names>Y</given-names></name><name><surname>Ferrell</surname><given-names>R</given-names></name><name><surname>Weeks</surname><given-names>D</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name><name><surname>van Duijn</surname><given-names>C</given-names></name><name><surname>Haines</surname><given-names>J</given-names></name><name><surname>Pericak-Vance</surname><given-names>M</given-names></name><name><surname>Gorin</surname><given-names>M</given-names></name></person-group><article-title>A pooled casecontrol study of the apolipoprotein E (APOE) gene in age-related maculopathy.</article-title><source>Ophthalmic Genet</source><year>2002</year><volume>23</volume><fpage>209</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12567264</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zareparsi</surname><given-names>S</given-names></name><name><surname>Reddick</surname><given-names>AC</given-names></name><name><surname>Branham</surname><given-names>KE</given-names></name><name><surname>Moore</surname><given-names>KB</given-names></name><name><surname>Jessup</surname><given-names>L</given-names></name><name><surname>Thoms</surname><given-names>S</given-names></name><name><surname>Smith-Wheelock</surname><given-names>M</given-names></name><name><surname>Yashar</surname><given-names>BM</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name></person-group><article-title>Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2004</year><volume>45</volume><fpage>1306</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15111581</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rivera</surname><given-names>A</given-names></name><name><surname>White</surname><given-names>K</given-names></name><name><surname>St&#x000f6;hr</surname><given-names>H</given-names></name><name><surname>Steiner</surname><given-names>K</given-names></name><name><surname>Hemmrich</surname><given-names>N</given-names></name><name><surname>Grimm</surname><given-names>T</given-names></name><name><surname>Jurklies</surname><given-names>B</given-names></name><name><surname>Lorenz</surname><given-names>B</given-names></name><name><surname>Scholl</surname><given-names>HP</given-names></name><name><surname>Apfelstedt-Sylla</surname><given-names>E</given-names></name><name><surname>Weber</surname><given-names>BH</given-names></name></person-group><article-title>A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene in Stargardt disease and age-related macular degeneration.</article-title><source>Am J Hum Genet</source><year>2000</year><volume>67</volume><fpage>800</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10958763</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allikmets</surname><given-names>R</given-names></name></person-group><article-title>Simple and complex ABCR: genetic predisposition to retinal disease.</article-title><source>Am J Hum Genet</source><year>2000</year><volume>67</volume><fpage>793</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10970771</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shukunami</surname><given-names>C</given-names></name><name><surname>Oshima</surname><given-names>Y</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name></person-group><article-title>Molecular cloning of tenomodulin, a novel chondromodulin-I related gene.</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>280</volume><fpage>1323</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11162673</pub-id></citation></ref><ref id="r36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamana</surname><given-names>K</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Kiyoki</surname><given-names>M</given-names></name></person-group><article-title>Molecular cloning and characterization of CHM1L, a novel membrane molecule similar to chondromodulin-I.</article-title><source>Biochem Biophys Res Commun</source><year>2001</year><volume>280</volume><fpage>1101</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11162640</pub-id></citation></ref><ref id="r37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brandau</surname><given-names>O</given-names></name><name><surname>Meindl</surname><given-names>A</given-names></name><name><surname>Fassler</surname><given-names>R</given-names></name><name><surname>Aszodi</surname><given-names>A</given-names></name></person-group><article-title>A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I.</article-title><source>Dev Dyn</source><year>2001</year><volume>221</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">11357195</pub-id></citation></ref><ref id="r38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oshima</surname><given-names>Y</given-names></name><name><surname>Shukunami</surname><given-names>C</given-names></name><name><surname>Honda</surname><given-names>J</given-names></name><name><surname>Nishida</surname><given-names>K</given-names></name><name><surname>Tashiro</surname><given-names>F</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Tano</surname><given-names>Y</given-names></name></person-group><article-title>Expression and localization of tenomodulin, a transmembrane type chondromodulin-I-related angiogenesis inhibitor, in mouse eyes.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2003</year><volume>44</volume><fpage>1814</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">12714610</pub-id></citation></ref><ref id="r39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oshima</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Tashiro</surname><given-names>F</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Nishida</surname><given-names>K</given-names></name><name><surname>Hiraki</surname><given-names>Y</given-names></name><name><surname>Tano</surname><given-names>Y</given-names></name><name><surname>Shukunami</surname><given-names>C</given-names></name></person-group><article-title>Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-I.</article-title><source>J Cell Sci</source><year>2004</year><volume>117</volume><fpage>2731</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">15150318</pub-id></citation></ref><ref id="r40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Docheva</surname><given-names>D</given-names></name><name><surname>Hunziker</surname><given-names>EB</given-names></name><name><surname>Fassler</surname><given-names>R</given-names></name><name><surname>Brandau</surname><given-names>O</given-names></name></person-group><article-title>Tenomodulin is necessary for tenocyte proliferation and tendon maturation.</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>699</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">15632070</pub-id></citation></ref><ref id="r41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tolppanen</surname><given-names>AM</given-names></name><name><surname>Pulkkinen</surname><given-names>L</given-names></name><name><surname>Kolehmainen</surname><given-names>M</given-names></name><name><surname>Schwab</surname><given-names>U</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Uusitupa</surname><given-names>M</given-names></name><collab>Finnish Diabetes Prevention Study Group.</collab></person-group><article-title>Tenomodulin is associated with obesity and diabetes risk: the Finnish Diabetes Prevention Study.</article-title><source>Obesity (Silver Spring)</source><year>2007</year><volume>15</volume><fpage>1082</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17495183</pub-id></citation></ref><ref id="r42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tolppanen</surname><given-names>AM</given-names></name><name><surname>Pulkkinen</surname><given-names>L</given-names></name><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Kolehmainen</surname><given-names>M</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Uusitupa</surname><given-names>M</given-names></name><collab>Finnish Diabetes Prevention Study Group.</collab></person-group><article-title>The genetic variation of the tenomodulin gene (TNMD) is associated with serum levels of systemic immune mediators&#x02013;the Finnish Diabetes Prevention Study.</article-title><source>Genet Med</source><year>2008</year><volume>10</volume><fpage>536</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">18580688</pub-id></citation></ref><ref id="r43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tolppanen</surname><given-names>AM</given-names></name><name><surname>Pulkkinen</surname><given-names>L</given-names></name><name><surname>Kuulasmaa</surname><given-names>T</given-names></name><name><surname>Kolehmainen</surname><given-names>M</given-names></name><name><surname>Schwab</surname><given-names>U</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Uusitupa</surname><given-names>M</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name></person-group><article-title>The genetic variation in the tenomodulin gene is associated with serum total and LDL cholesterol in a body size-dependent manner.</article-title><source>Int J Obes (Lond)</source><year>2008</year><volume>32</volume><fpage>1868</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">18982016</pub-id></citation></ref><ref id="r44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Joo</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Geller</surname><given-names>NL</given-names></name></person-group><article-title>Testing association for markers on the X chromosome.</article-title><source>Genet Epidemiol</source><year>2007</year><volume>31</volume><fpage>834</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">17549761</pub-id></citation></ref><ref id="r45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><name><surname>Pe'er</surname><given-names>I</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name></person-group><article-title>Efficiency and power in genetic association studies.</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>1217</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16244653</pub-id></citation></ref><ref id="r46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="r47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tregouet</surname><given-names>DA</given-names></name><name><surname>Escolano</surname><given-names>S</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Mallet</surname><given-names>A</given-names></name><name><surname>Golmard</surname><given-names>JL</given-names></name></person-group><article-title>A new algorithm for haplotypebased association analysis: the Stochastic-EM algorithm.</article-title><source>Ann Hum Genet</source><year>2004</year><volume>68</volume><fpage>165</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">15008795</pub-id></citation></ref><ref id="r48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>JD</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><article-title>Statistical significance for genomewide studies.</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>9440</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12883005</pub-id></citation></ref><ref id="r49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carrel</surname><given-names>L</given-names></name><name><surname>Willard</surname><given-names>HF</given-names></name></person-group><article-title>X-inactivation profile reveals extensive variability in X-linked gene expression in females.</article-title><source>Nature</source><year>2005</year><volume>434</volume><fpage>400</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15772666</pub-id></citation></ref><ref id="r50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolehmainen</surname><given-names>M</given-names></name><name><surname>Salopuro</surname><given-names>T</given-names></name><name><surname>Schwab</surname><given-names>US</given-names></name><name><surname>Kek&#x000e4;l&#x000e4;inen</surname><given-names>J</given-names></name><name><surname>Kallio</surname><given-names>P</given-names></name><name><surname>Laaksonen</surname><given-names>DE</given-names></name><name><surname>Pulkkinen</surname><given-names>L</given-names></name><name><surname>Lindi</surname><given-names>VI</given-names></name><name><surname>Sivenius</surname><given-names>K</given-names></name><name><surname>Mager</surname><given-names>U</given-names></name><name><surname>Siitonen</surname><given-names>N</given-names></name><name><surname>Niskanen</surname><given-names>L</given-names></name><name><surname>Gylling</surname><given-names>H</given-names></name><name><surname>Rauramaa</surname><given-names>R</given-names></name><name><surname>Uusitupa</surname><given-names>M</given-names></name></person-group><article-title>Weight reduction modulates expression of genes involved in extracellular matrix and cell death: the GENOBIN study.</article-title><source>Int J Obes (Lond)</source><year>2008</year><volume>32</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">17848939</pub-id></citation></ref><ref id="r51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>PL</given-names></name><name><surname>Bakalov</surname><given-names>VK</given-names></name><name><surname>Zinn</surname><given-names>AR</given-names></name><name><surname>Bondy</surname><given-names>CA</given-names></name></person-group><article-title>Maternal X chromosome, visceral adiposity, and lipid profile.</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>1373</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">16551706</pub-id></citation></ref><ref id="r52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Snyder</surname><given-names>M</given-names></name></person-group><article-title>Sexual dimorphism in mammalian gene expression.</article-title><source>Trends Genet</source><year>2005</year><volume>21</volume><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">15851067</pub-id></citation></ref><ref id="r53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zarbin</surname><given-names>MA</given-names></name></person-group><article-title>Current concepts in the pathogenesis of age-related macular degeneration.</article-title><source>Arch Ophthalmol</source><year>2004</year><volume>122</volume><fpage>598</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">15078679</pub-id></citation></ref><ref id="r54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grisanti</surname><given-names>S</given-names></name><name><surname>Tatar</surname><given-names>O</given-names></name></person-group><article-title>The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration.</article-title><source>Prog Retin Eye Res</source><year>2008</year><volume>27</volume><fpage>372</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18621565</pub-id></citation></ref><ref id="r55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Hillan</surname><given-names>KJ</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name></person-group><article-title>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.</article-title><source>Nat Rev Drug Discov</source><year>2004</year><volume>3</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">15136787</pub-id></citation></ref><ref id="r56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gragoudas</surname><given-names>ES</given-names></name><name><surname>Adamis</surname><given-names>AP</given-names></name><name><surname>Cunningham</surname><given-names>ET</given-names><suffix>Jr</suffix></name><name><surname>Feinsod</surname><given-names>M</given-names></name><name><surname>Guyer</surname><given-names>DR</given-names></name><name><surname>Inhibition</surname><given-names>VEGF</given-names></name></person-group><article-title>Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2004</year><volume>351</volume><fpage>2805</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15625332</pub-id></citation></ref><ref id="r57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><name><surname>Michels</surname><given-names>M</given-names></name><name><surname>Soubrane</surname><given-names>G</given-names></name><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>RY</given-names></name><name><surname>Sy</surname><given-names>JP</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><collab>ANCHOR Study Group.</collab></person-group><article-title>Ranibizumab versus verteporfin for neovascular age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>1432</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">17021319</pub-id></citation></ref><ref id="r58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenfeld</surname><given-names>PJ</given-names></name><name><surname>Brown</surname><given-names>DM</given-names></name><name><surname>Heier</surname><given-names>JS</given-names></name><name><surname>Boyer</surname><given-names>DS</given-names></name><name><surname>Kaiser</surname><given-names>PK</given-names></name><name><surname>Chung</surname><given-names>CY</given-names></name><name><surname>Kim</surname><given-names>RY</given-names></name><collab>MARINA Study Group.</collab></person-group><article-title>Ranibizumab for neovascular age-related macular degeneration.</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>1419</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">17021318</pub-id></citation></ref><ref id="r59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boekhoorn</surname><given-names>SS</given-names></name><name><surname>Isaacs</surname><given-names>A</given-names></name><name><surname>Uitterlinden</surname><given-names>AG</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>de Jong</surname><given-names>PT</given-names></name><name><surname>Vingerling</surname><given-names>JR</given-names></name></person-group><article-title>Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration: the Rotterdam Study.</article-title><source>Ophthalmology</source><year>2008</year><volume>115</volume><fpage>1899</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">18708255</pub-id></citation></ref><ref id="r60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Churchill</surname><given-names>AJ</given-names></name><name><surname>Carter</surname><given-names>JG</given-names></name><name><surname>Lovell</surname><given-names>HC</given-names></name><name><surname>Ramsden</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>SJ</given-names></name><name><surname>Yeung</surname><given-names>A</given-names></name><name><surname>Escardo</surname><given-names>J</given-names></name><name><surname>Atan</surname><given-names>D</given-names></name></person-group><article-title>VEGF polymorphisms are associated with neovascular age-related macular degeneration.</article-title><source>Hum Mol Genet</source><year>2006</year><volume>15</volume><fpage>2955</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">16940309</pub-id></citation></ref><ref id="r61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JM</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Tsai</surname><given-names>YY</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name><name><surname>Tsai</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name></person-group><article-title>Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>145</volume><fpage>1045</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">18378209</pub-id></citation></ref><ref id="r62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Schnetz-Boutaud</surname><given-names>N</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Postel</surname><given-names>EA</given-names></name><name><surname>Olson</surname><given-names>L</given-names></name><name><surname>Kenealy</surname><given-names>SJ</given-names></name><name><surname>Hauser</surname><given-names>M</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name></person-group><article-title>Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6.</article-title><source>Invest Ophthalmol Vis Sci</source><year>2006</year><volume>47</volume><fpage>329</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">16384981</pub-id></citation></ref><ref id="r63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JM</given-names></name><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Tsai</surname><given-names>YY</given-names></name><name><surname>Lin</surname><given-names>HJ</given-names></name><name><surname>Tsai</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Tseng</surname><given-names>SH</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name></person-group><article-title>Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration.</article-title><source>Am J Ophthalmol</source><year>2008</year><volume>145</volume><fpage>716</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18226801</pub-id></citation></ref><ref id="r64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Takeuchi</surname><given-names>M</given-names></name></person-group><article-title>Met72Thr polymorphism of pigment epithelium-derived factor gene and susceptibility to age-related macular degeneration.</article-title><source>Med Hypotheses</source><year>2005</year><volume>64</volume><fpage>1202</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15823717</pub-id></citation></ref></ref-list></back></article> 